Amyndas Pharmaceuticals is focused on developing advanced complement therapeutics, particularly through its lead compound, AMY-101, which targets the complement system to address various inflammatory diseases. The company has created next-generation Compstatins that exhibit significantly enhanced binding affinity and inhibitory potency against human complement component C3, with a prolonged half-life in vivo. This innovative approach allows for targeted inhibition of complement activation, which is crucial in managing conditions characterized by excessive inflammation, such as COVID-19, periodontal disease, and age-related macular degeneration. Additionally, Amyndas has developed compounds like Compsorbin and factor H mini constructs to further enhance complement inhibition on cell surfaces, showcasing a commitment to advancing therapeutic options for patients with unmet medical needs.

The therapeutic potential of AMY-101 extends to several clinical applications, including its use in preventing organ rejection in kidney transplantation and treating rare conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and C3 glomerulopathy (C3G). The company is also exploring the combination of AMY-101 with cancer immunotherapy, particularly in conjunction with PD-L1 inhibitors, to enhance anti-tumor responses. With a robust pipeline and ongoing clinical trials, Amyndas Pharmaceuticals aims to provide innovative solutions for diseases driven by dysregulated complement activity, thereby improving patient outcomes in various inflammatory and immune-mediated disorders.

United States

Amyndas is a pharmaceutical company developing potent complement therapeutics for inflammatory diseases and disorders based on its patented technology for modulating the complement system.

Amyndas Pharmaceuticals

Company Details